ArticleJournal of applied clinical medical physics2025
Feasibility of treatment planning with HyperArc stereotactic radiosurgery methods for ocular tumors.
Article in Journal of applied clinical medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility of treatment planning with HyperArc stereotactic radiosurgery methods for ocular tumors.Journal of applied clinical medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PURPOSE/
objectivesCurrently, ocular disease is primarily managed with COMS plaque brachytherapy. Various stereotactic radiosurgery (SRS) platforms have also been employed, yet widespread access remains a challenge. Herein, we demonstrate the feasibility of using the HyperArc SRS system to provide an additional platform for the treatment of ocular malignancies. MATERIALS/
methodsTwenty previously treated COMS patients with ocular melanoma were selected for a retrospective HyperArc SRS planning study. The average gross tumor volume (GTV) derived from MRI was 1.19 ± 0.60 cc. Planning target volumes (PTV) were generated from a 2 mm expansion of the GTVs. HyperArc plans were created for a TrueBeam LINAC (6MV-FFF) with the Encompass support system and used the AcurosXB algorithm for dose calculation. A dose of 25 Gy was prescribed to the PTVs and all plans were normalized such that PTVD95% = 25 Gy. All organs at risk (OARs) were spared adequately. Patient-specific quality assurance (QA) and an independent Monte Carlo (MC) second check was performed for all SRS plans.
resultsHyperArc plans demonstrated high conformality Paddick conformity index (PCI = 0.84 ± 0.04) with steep dose gradient index (GI = 3.29 ± 0.38). Compared to the HyTEC standard (12.1 Gy), it adequately spared the optic nerve(s) (Dmax = 7.18 ± 1.26 Gy, p < 0.001). Adequate PTV coverage (D99% = 23.80 ± 0.46 Gy) was achieved with a mean GTV dose of 27.54 ± 0.47 Gy. Maximum dose to critical OARs were controlled: brain (6.00 ± 1.50 Gy), optic nerve (7.18 ± 1.26 Gy), and ipsilateral lens (9.36 ± 5.67 Gy). Average beam-on time was under 9 min. End-to-end QA results showed a 99.00 ± 0.59% pass rate (2%/2 mm γ-criteria), with a MC check showing 97.81 ± 1.24% agreement with the AcurosXB algorithm (2%/2 mm).
conclusionHyperArc SRS plans provided adequate target coverage, acceptable OARs sparing, and offer a fast, safe, and non-invasive treatment option for ocular tumors. Clinical implementation of this novel methodology is ongoing at our institution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.